Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) receptor , is exhibiting promising outcomes in preliminary human trials . Current research https://greatbookmarking.com/story21395917/retatrutide-emerging-studies-and-possible-clinical-uses